About this Research Topic
Despite extensive studies, cancer remains one of the most dreadful diagnoses and biggest challenges for human health all over the world, representing a leading cause of death in the industrialized countries.
Various chemotherapeutic drugs, such as Doxorubicin, Tamoxifen and Paclitaxel, have been used for the treatment of tumours for more than half a century; however, there are still no curative options currently available in clinical settings and the severe adverse effects of these drugs threaten the well-being of the patients seriously.
Current evidence suggests that further knowledge is urgently needed to clarify the unknown properties and molecular mechanisms of action of various chemopreventive molecules.
Several small molecules either of biological origin or from synthetic chemistry, such as cordycepin, mitomycin C, doxorubicin and methotrexate, have demonstrated great efficacy towards a variety of cancers. These agents are found to suppress the proliferation of cancer cells by various mechanisms such as apoptotic cell death, cancer cell cycle arrest, inhibition of angiogenesis and metastasis, induction of ROS generation etc.
Few in silico tools, such as docking and QSAR (Quantitative structure-activity relationship) techniques, can be used to retrieve more comprehensive information about the targets and the action mechanisms of such molecules.
However, there has been a vigorous need to explore the acute as well as the chronic toxicological effects of such chemopreventive molecules for further clinical implementation against diseases.
This Research Topic aims to highlight the ongoing advancement in chemopreventive and therapeutical approaches, as well as the promising role of the above mentioned agents in the context of cancer prevention and therapy.
In particular, the specific objective of this collection is to gather the results of well-designed in silico, in vitro and ,in vivo preclinical studies, in addition to randomized double blind multi-centred clinical trials designed to decrease the adverse actions of these drugs and to draw scientists’ attention towards precision and personalized medicine in cancer patients by performing targeted therapies.
The present Research Topic welcomes high-quality Original Research as well as Review articles providing:
• Strategies for cancer chemoprevention using natural medicine;
• Novel in vitro/in vivo approaches in cancer treatment using animal cell culture or animal studies;
• Mechanistic insight of anti-cancer agents such as apoptosis induction, cell cycle arrest, anti-angiogenesis, anti-metastasis, etc.;
• Nano-drug delivery systems in cancer treatment;
• Synthetic and semisynthetic molecules and their anti-cancer activities;
• In silico techniques such as docking and QSAR techniques for designing novel drug candidates;
• Synergistic effects of chemopreventive agents with existing chemotherapeutic drugs;
• Drug resistance mechanisms in cancer;
• Targeted therapies with monoclonal antibodies.
Various chemotherapeutic drugs, such as Doxorubicin, Tamoxifen and Paclitaxel, have been used for the treatment of tumours for more than half a century; however, there are still no curative options currently available in clinical settings and the severe adverse effects of these drugs threaten the well-being of the patients seriously.
Current evidence suggests that further knowledge is urgently needed to clarify the unknown properties and molecular mechanisms of action of various chemopreventive molecules.
Several small molecules either of biological origin or from synthetic chemistry, such as cordycepin, mitomycin C, doxorubicin and methotrexate, have demonstrated great efficacy towards a variety of cancers. These agents are found to suppress the proliferation of cancer cells by various mechanisms such as apoptotic cell death, cancer cell cycle arrest, inhibition of angiogenesis and metastasis, induction of ROS generation etc.
Few in silico tools, such as docking and QSAR (Quantitative structure-activity relationship) techniques, can be used to retrieve more comprehensive information about the targets and the action mechanisms of such molecules.
However, there has been a vigorous need to explore the acute as well as the chronic toxicological effects of such chemopreventive molecules for further clinical implementation against diseases.
This Research Topic aims to highlight the ongoing advancement in chemopreventive and therapeutical approaches, as well as the promising role of the above mentioned agents in the context of cancer prevention and therapy.
In particular, the specific objective of this collection is to gather the results of well-designed in silico, in vitro and ,in vivo preclinical studies, in addition to randomized double blind multi-centred clinical trials designed to decrease the adverse actions of these drugs and to draw scientists’ attention towards precision and personalized medicine in cancer patients by performing targeted therapies.
The present Research Topic welcomes high-quality Original Research as well as Review articles providing:
• Strategies for cancer chemoprevention using natural medicine;
• Novel in vitro/in vivo approaches in cancer treatment using animal cell culture or animal studies;
• Mechanistic insight of anti-cancer agents such as apoptosis induction, cell cycle arrest, anti-angiogenesis, anti-metastasis, etc.;
• Nano-drug delivery systems in cancer treatment;
• Synthetic and semisynthetic molecules and their anti-cancer activities;
• In silico techniques such as docking and QSAR techniques for designing novel drug candidates;
• Synergistic effects of chemopreventive agents with existing chemotherapeutic drugs;
• Drug resistance mechanisms in cancer;
• Targeted therapies with monoclonal antibodies.
Keywords: Anti-cancer agents, Apoptosis induction, Anti-angiogenesis, Anti-metastasis, Anti-inflammation
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
